XTANDI Drug Patent Profile

Which patents cover Xtandi, and what generic alternatives are available?

Xtandi is a drug marketed by Astellas and is included in two NDAs. There are seven patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in thirty-six countries.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xtandi

A generic version of XTANDI was approved as enzalutamide by SANDOZ on April 20^th, 2026.

Summary for XTANDI

International Patents:	192
US Patents:	7
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	155
Patent Applications:	4,863
Drug Prices:	Drug price information for XTANDI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XTANDI
What excipients (inactive ingredients) are in XTANDI?	XTANDI excipients list
DailyMed Link:	XTANDI at DailyMed

See drug prices for XTANDI

Recent Clinical Trials for XTANDI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	Phase 3
Orion Corporation, Orion Pharma	Phase 3
Prostate Cancer Foundation	Phase 1/Phase 2

See all XTANDI clinical trials

Pharmacology for XTANDI

Drug Class	Androgen Receptor Inhibitor
Mechanism of Action	Androgen Receptor Antagonists Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers

Paragraph IV (Patent) Challenges for XTANDI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTANDI	Tablets	enzalutamide	120 mg and 160 mg	213674	1	2024-12-27
XTANDI	Tablets	enzalutamide	40 mg and 80 mg	213674	1	2021-03-31
XTANDI	Capsules	enzalutamide	40 mg	203415	3	2016-08-31

US Patents and Regulatory Information for XTANDI

XTANDI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	12,502,357
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	7,709,517		Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No	7,709,517		Y	Y
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes	8,183,274

Expired US Patents for XTANDI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	9,126,941
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012	9,126,941
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	9,126,941

EU/EMA Drug Approvals for XTANDI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Xtandi	enzalutamide	EMEA/H/C/002639Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.	Authorised	no	no	no	2013-06-21	2013-04-26

International Patents for XTANDI

When does loss-of-exclusivity occur for XTANDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Israel

Russian Federation

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XTANDI around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017027665
Austria	E541571
Australia	2006248109	Diarylhydantoin compounds
Australia	2007245022	Diarylthiohydantoin compounds
Brazil	PI0610359	composto de diaril-hidantoìna, método de sintetização de compostos e método in vitro

Supplementary Protection Certificates for XTANDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893196	C300632	Netherlands		PRODUCT NAME: ENZALUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/846 20130621
1893196	CA 2013 00065	Denmark		PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
1893196	PA2013029	Lithuania		PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130621
1893196	1390060-0	Sweden		PRODUCT NAME: ENZALUTAMID OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/13/846 20130621
1893196	C20130036 00106	Estonia		PRODUCT NAME: ENSALUTAMIID;REG NO/DATE: K(2013)4019 (LOPLIK) 25.06.2013

XTANDI (enzalutamide) market dynamics and financial trajectory: sales drivers, price pressure, and exclusivity and generic risk

Last updated: June 23, 2026

Executive summary

• XTANDI (enzalutamide) has moved from rapid growth into a mature, contestable market defined by: (1) expanded clinical placement across prostate cancer stages, (2) steady label breadth and guideline penetration, and (3) growing competition from abiraterone sequencing, docetaxel intensification, and androgen receptor (AR) pathway competitors.
• Financial trajectory is shaped by global revenue concentration (US and EU), patent/exclusivity timing by geography, and the speed and depth of payer access tightening as generic and biosimilar-style price compression analogs play out through formularies and contracting.
• The business risk profile stays dominated by loss of composition-of-matter and formulation protection (where applicable) and by regulatory and patent litigation outcomes that can delay generic/authorized-competition entry. The market is also exposed to indication-specific displacement, not just “molecule-level” generic threats.

---

What is XTANDI used for, and where does it generate sales across prostate cancer?

Featured snippet answer: XTANDI (enzalutamide) is used to treat prostate cancer across multiple lines and stages, generating sales through broad guideline adoption and continued payer coverage where clinical benefit is preserved.

Therapeutic footprint that drives revenue durability

XTANDI is positioned in metastatic castration-resistant prostate cancer (mCRPC) and has expanded into earlier settings where treatment sequencing is favorable. Market dynamics are driven by:

• Line-of-therapy mix (earlier use can raise volume even if later lines decline).
• Subpopulation performance (patients who respond and remain on treatment drive per-patient revenue).
• Site-of-care contracting (hospital vs office administration patterns can shift net pricing).
• Utilization management (prior authorization intensity can cap uptake even with label breadth).

Key market segments

• mCRPC: core revenue engine where AR pathway inhibition remains central.
• Non-metastatic castration-resistant prostate cancer (nmCRPC): volume growth when payers accept risk-benefit and budgets permit.
• Metastatic hormone-sensitive prostate cancer (mHSPC): adds earlier demand, but may reduce later-line opportunity depending on sequencing.

---

How have XTANDI sales evolved over time, and what has driven the financial trajectory?

Featured snippet answer: XTANDI revenue has historically benefited from label expansion and sustained market access, then transitions into a mature sales curve as competition increases and payer pressure rises.

Phase 1: Growth from clinical evidence and broad placement

Typical drivers in early years:

• Rapid guideline uptake after pivotal efficacy datasets.
• Conversion from chemotherapy-based paradigms in populations that respond to AR pathway blockade.
• Institutional adoption where urology and oncology pathways standardize prescribing.

Phase 2: Plateau to mature trajectory

As the market matures:

• New launches from AR competitors can steal share at similar efficacy tiers.
• Sequencing changes (abiraterone-first vs enzalutamide-first) shift demand between brands.
• Payer contracting moves from blanket coverage to indication-specific tiering and step therapy.

Phase 3: Commercial stress from pricing pressure and competing mechanisms

Market dynamics become:

• Net price compression from rebates, discounts, and formulary tiering.
• Increased competition from second-generation AR inhibitors and combination regimens.
• Shift toward cost-effectiveness and tighter payer thresholds.

Business implication: XTANDI’s financial trajectory is not governed only by molecule-level competition. It is governed by indication-level displacement and net pricing mechanics in each geography.

---

What market dynamics most affect XTANDI revenue today?

Featured snippet answer: XTANDI revenue is most sensitive to payer access, sequencing in AR-targeted care pathways, and competitive substitution among androgen receptor inhibitors and chemotherapy intensification.

Payer access, net pricing, and reimbursement pressure

Primary dynamics:

• Formulary positioning in Medicare Part D and commercial PBMs.
• Prior authorization tightening as competitors enter and payers implement evidence-of-response rules.
• Contracting leverage as manufacturers face more SKU-level competition in mCRPC and nmCRPC.

Net price effects:

• Rising rebates and payer discounts reduce realized revenue even if gross demand holds.
• Competition increases the frequency of market-wide tendering and channel-based contracting.

Clinical sequencing and displacement dynamics

Common drivers of share changes:

• If a competitor demonstrates superior outcomes in a subpopulation or specific sequence, enzalutamide share declines even without generic entry.
• Combination uptake can restructure the market around regimens rather than monotherapy.

Treatment duration and discontinuation

Financial impact:

• Better tolerated regimens or faster-moving standards can shorten on-drug time or reduce persistence.
• Real-world adherence and dose management affect per-patient revenue and downstream cost offsets that influence payer acceptance.

---

What does the competitive landscape look like for XTANDI?

Featured snippet answer: XTANDI competes in a crowded prostate cancer market with multiple AR pathway inhibitors and chemotherapy-based approaches. Brand share is increasingly contested on guideline placement and payer contracting rather than only initial efficacy.

Competitor set by mechanism and clinical positioning

• AR pathway inhibitors: competing agents in mCRPC and earlier stages, often selected based on prior abiraterone exposure, metastasis status, and payer preference.
• Chemotherapy: docetaxel intensification and post-AR strategies.
• Combination and targeted approaches: where emerging standards shift the prescribing base.

What matters for competitive share

• Comparative outcomes in key subgroups.
• Tolerability and administration convenience.
• Evidence strength tied to payer thresholds for continuation.

---

When does XTANDI lose exclusivity, and what is the generic entry risk by geography?

Featured snippet answer: Generic and authorized-competition entry risk increases as key patent and regulatory exclusivity barriers fall by jurisdiction. The practical timing for entry depends on which patents are asserted and whether litigation settles or proceeds to judgment.

Exclusivity and patent risk framework

Market entry risk is driven by:

• Composition-of-matter patent expirations
• Method-of-use patent expirations
• Formulation and dosing regimen patents
• Regulatory exclusivity (where applicable)
• Litigation status that can trigger stays or delay launch

How to read the risk

• A “molecule is off-patent” headline is not the same as “generic can launch.” Launch depends on:
  • Whether an ANDA paragraph IV challenge has been resolved
  • Whether injunctions or settlements restrict launch timing
  • Whether covered patents remain in force

---

What Orange Book status typically governs XTANDI entry, and how many patents matter?

Featured snippet answer: XTANDI’s Orange Book listing is the gating item for ANDA entry. Launch feasibility depends on which listed patents are still enforceable and whether they are successfully challenged.

Patent categories that block generic entry

• Drug substance (composition-of-matter)
• Drug product (formulation, dosage form, stability)
• Method-of-use (indications, dosing regimens, patient selection criteria)

Practical market outcome

• Even when composition-of-matter protection is near-term, method-of-use and product patents can preserve brand value by delaying generic launch for specific indication labeling or dosing presentations.

---

How do Paragraph IV challenges and settlements usually affect XTANDI’s financial outlook?

Featured snippet answer: Patent litigation outcomes and settlement timing can delay generic entry and preserve pricing, reducing near-term revenue volatility.

Mechanics impacting time-to-competition

• Paragraph IV filing often indicates a competitor’s intent to launch at risk.
• FDA approval timelines and 180-day exclusivity (for first filers) can structure competitive entry waves.
• Court rulings vs settlements affect whether entry occurs immediately at patent expiry or after design-around.

Business impact

• Settlements often convert uncertainty into predictable launch dates and can preserve cash flows.
• Litigation duration can compress or extend forecast horizons by delaying entry.

---

Is XTANDI facing biosimilar-like competition risk?

Featured snippet answer: Biosimilar-style risks do not apply in the same way because XTANDI is a small-molecule drug. The dominant risk category is generic and authorized-competition rather than biosimilars.

Why this matters commercially

• Generic competition dynamics are usually faster at scale than biologic substitution.
• The primary lever for XTANDI defense is maintaining pricing and contracting while exclusivity barriers persist.

---

What formulations are protected, and how does that affect generic design-around?

Featured snippet answer: Product and formulation patents can delay full generic substitution by constraining bioequivalence-acceptable designs for the market’s dominant presentations.

Formulation patent logic that blocks entry

• If formulation patents cover excipients, stability, or release characteristics, generics may need design changes.
• Even when bioequivalence is possible, patent coverage can restrict labeled substitution or launch timing.

---

How does XTANDI pricing and contracting behavior shape net revenue?

Featured snippet answer: XTANDI net revenue depends on rebate intensity, formulary tiering, and step therapy, which tighten as competitors increase and as launch risk rises.

Key commercial variables

• PBM contracting and percentage discounts
• Hospital group purchasing practices
• Government pricing rules and utilization caps
• Indication-based access rules

Revenue effect

• Net revenue declines can precede volume declines.
• Payer pressure is most acute during transitions toward earlier-line standards and when competing products expand formulary footprint.

---

What patent litigation and enforcement posture has influenced XTANDI’s market access?

Featured snippet answer: Litigation outcomes influence whether generic entry occurs at expiry, is enjoined, or is delayed via settlements and launch design.

Why enforcement drives market economics

• Injunctions can preserve pricing and market share until resolution.
• Settlements can shift the entry calendar from “on paper” to “in practice.”

(This analysis requires case-specific docketing and Orange Book patent mapping; no complete, reliable litigation record is included in the provided materials.)

---

How does XTANDI compare with other prostate cancer AR inhibitors on commercial durability?

Featured snippet answer: AR inhibitors with stronger payer positioning and broader tolerability advantages tend to show better commercial durability. XTANDI’s durability depends on its label breadth and contracting strength more than on any single-patent factor.

Comparison dimensions

• Guideline and payer acceptance in mCRPC and earlier indications
• Real-world persistence and dose management
• Net price and formulary tier stability
• Vulnerability window to generic entry once key patents fall

---

What is the revenue exposure to each indication in XTANDI’s business model?

Featured snippet answer: Indication mix determines resilience. Earlier-line penetration can stabilize volume, while late-line share is more sensitive to treatment sequencing and competition intensity.

Exposure drivers

• Proportion of patients treated in mCRPC vs nmCRPC vs mHSPC
• Time-to-progression and discontinuation rates
• Prescribing behavior by oncologists vs urologists
• Payer-driven restriction on access for non-priority stages

---

Key Takeaways

• XTANDI’s financial trajectory is dominated by payer access, net pricing compression, and AR-sequencing competition, not only by generic launch timing.
• Generic entry risk is governed by Orange Book patent coverage and litigation outcomes, which can preserve pricing through settlements or injunctions even if some headline patents expire.
• The main near-to-mid term commercial variable is indication-level displacement: competitor uptake can reduce share before patents fall.
• Biosimilar risk is not a primary factor for XTANDI; the dominant substitution channel is generic/authorized-competition.

---

FAQs

1) What drives XTANDI net revenue more: volume or net price?
Net revenue is typically more sensitive to net pricing through rebates and formulary tiering as competition rises; volume declines often lag payer actions.

2) What is the biggest commercial threat to XTANDI before generic entry?
Indication-level substitution driven by clinical sequencing changes and competitive AR inhibitor placement on formularies.

3) How do Orange Book patents affect the timing of generic availability for XTANDI?
Generic timing depends on which listed patents remain enforceable and whether paragraph IV challenges and litigation result in launch restrictions.

4) Do formulation patents matter for XTANDI competition?
Yes. Formulation and product patents can delay “market substitution” by constraining design-around options or delaying labeled launches.

5) Is XTANDI’s future mainly a patent-expiry story?
Patent expiry matters, but payer contracting and competitor displacement can reduce net revenue and share well before final patent barriers fall.

DrugChatter Q&A for XTANDI

Expected xtandi loe in japan answersnews press release?
Is astellas xtandi patent ending soon?
When is patent expiry for xtandi in hk?
When in 2027 is xtandi patent ending?
Astellas gears up for xtandi patent cliff with next gen assets cost cut?